DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

DexCom (NASDAQ:DXCM) will release its earnings report on Thursday, May 1, 2025. Historically, the stock has exhibited significant volatility around its earnings announcements. Over the past five years ...

People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...

As reimbursement broadens globally, DexCom is well positioned to drive sustained user growth and strengthen its leadership in ...

VIENNA--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...